Key result
Cancer therapy toxicities impair the entire oxygen pathway, driving CV risk and exercise intolerance.
Why the study?
Cardiovascular disease is the leading cause of disability and death for many early-stage cancers, prompting the need to consider toxicities from cancer therapeutics beyond the heart.
How do cancer therapies impact peak oxygen uptake and cardiovascular disease risk beyond direct cardiac injury?
How do cancer therapies impact peak oxygen uptake and cardiovascular disease risk beyond direct cardiac injury?
Understanding the broad effects of cancer therapies on the entire oxygen pathway, beyond just direct cardiac injury, is crucial for identifying and managing cardiovascular risk in cancer survivors.
Supports holistic oxygen pathway assessment in cancer survivors; leaves open targeted intervention trials beyond cardiac monitoring.
The landscape of cancer therapeutics is continually evolving, with successes in improved survivorship and reduced disease progression for many patients with cancer. Improved cancer outcomes expose competing comorbidities, some of which may be exacerbated by cancer therapies. The leading cause of disability and death for many early-stage cancers is cardiovascular disease (CVD), which is often attributed to direct or indirect cardiac injury from cancer therapy. In this review, the authors propose that toxicities related to conventional and novel cancer therapeutics should be considered beyond the heart. The authors provide a framework using the oxygen pathway to understand the impact of cancer treatment on peak oxygen uptake, a marker of integrative cardiopulmonary function and CVD risk. Peripheral toxicities and the impact on oxygen transport are discussed. Consideration for the broad effects of cancer therapies will improve the prediction and identification of cancer survivors at risk for CVD, functional disability, and premature mortality and those who would benefit from therapeutic intervention, ultimately improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Dillon et al. (2024) conducted a review in Cancer therapy-related cardiovascular disease and exercise intolerance. Cancer therapy was evaluated. Cancer therapy toxicities extend beyond direct cardiac injury, impacting the entire oxygen pathway and peak oxygen uptake, which contributes to cardiovascular disease risk and exercise intolerance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: